Patient Education
5 articles on Patient Education, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Safety: FDA Action, TrumpRx Access & Weight Loss Drug Risks
Explore the critical safety differences between compounded GLP-1 medications and FDA-approved treatments. Understand the role of new access programs in combating unsafe alternatives.
9 min read
GLP-1 Weight Loss Drugs and Hair Loss: What the New Study Reveals
Recent findings suggest a connection between GLP-1 agonists and temporary hair shedding. Discover the science, risk factors, and how to manage this side effect while on weight loss therapy.
6 min read
Beyond Weight Loss: Understanding GLP-1 Side Effects & Solutions
The rise of GLP-1 medications like Ozempic and Mounjaro has brought significant advancements in weight management and diabetes care. However, as more individuals embrace these therapies, understanding and managing potential side effects becomes crucial for a successful health journey.
7 min read
GLP-1 Weight Loss: What Happens When You Stop Semaglutide or Tirzepatide?
A comprehensive analysis of recent data shows that stopping GLP-1 medications like Ozempic and Wegovy often leads to weight regain and a return of cardiometabolic risk markers. Here is what you need to know about long-term outcomes and maintenance strategies.
7 min read
GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia
Emerging reports suggest GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may trigger unusual sensory side effects, including painful skin sensitivity known as dysesthesia and allodynia. A new case series provides critical insights for patients and clinicians.
7 min read